Excerpts of Human Studies of Pretargeted Nuclear Medicine Using Streptavidin–Biotin System
| Antibody radioligand pair and pretargeting timeline | Radioligand dose | Target antigen and study population | Main findings | Reference |
|---|---|---|---|---|
| Hour 0: Biotinylated antitenascin mAb BC4 Hour 36: (strept)avidin CA Hour 54–60: 90Y-DOTA-biotin | 2.22–2.96 GBq/m2 | Tenascin and high-grade glioma patients | Reduction in tumor in 25% patients, all patients developed immune response. | (8) |
| Hour 0: SA-conjugated C2B8 mAb Hour 34: biotin CA Hour 52: 111In/90Y-DOTA-biotin | 3–5 mCi (111In), 30–50 mCi/m2 (90Y) | CD20 and non-Hodgkin lymphoma patients | Good tumor–to–whole-body ratios (38:1), mild hematologic toxicity, 28% of patients with CR. | (12) |
| Hour 0: SA-conjugated NR-LU-10 mAb Hour 24–72: Biotin-galactose-HSA CA Hour 28–96: 111In/90Y-DOTA-biotin | 185 MBq (111In), 370 MBq/m2 (90Y) | Ep-CAM and adenocarcinoma patients (majority colorectal and lung) | Good tumor-to-marrow absorbed dose ratio (63:1), all tested patients developed immune response. | (16) |
| Hour 0: Biotinylated antitenascin mAb BC4 Hour 24: avidin CA Hour 42: 90Y-DOTA-biotin (procedure repeated again 8–10 wk apart) | 0.555–1.110 GBq | Tenascin and recurrent high-grade glioma, anaplastic astrocytoma patients | 25% overall response to PRIT, no hematologic toxicity observed. | (14) |
| Hour 0: Biotinylated antitenascin mAb BC4 Hour 24–36: avidin CA Hour 40–54: 90Y-DOTA-biotin | 2.2 GBq/m2 | Tenascin and high-grade glioma patients | Significantly higher OS in treated cohort than in control. | (15) |
| Hour 0: SA-conjugated CC49-(scFv)4 Hour 48/72: biotin CA Hour 72/96: 111In/90Y-DOTA-biotin | 185 MBq (111In), 370 MBq/m2 (90Y) | TAG-72 and metastatic colorectal cancer | Tumor–to–normal-tissue dose ratio 54.5, immune response or toxicity not reported. | (11) |
CR = complete response; SA = streptavidin; OS = overall survival.